Journal: Scientific Reports

Article Title: KIN17 facilitates the initiation and progression of renal tumor progression through the PI3K-AKT-mTOR pathway

doi: 10.1038/s41598-026-35851-5

Figure Lengend Snippet: KIN17 positively regulates PI3K/AKT/mTOR expression in RCC and PF-04691502 can reverse the pathway protein expression and biological function. ( A ) Predict effects of KIN17 knockdown on the pathways of RCC cells (ACHN and 786–0) in vitro by kegg and GSEA. ( B ) p-mTOR, mTOR, p-AKT, AKT, p-PI3K and PI3K protein levels were measured by WB using the paired RCC cells (ACHN and 786–0) group and knockdown KIN17 group. ( C ) p-mTOR, mTOR, p-AKT, AKT, p-PI3K and PI3K protein levels were measured by WB using the paired RCC vector cells group (VE groups), overexpression KIN17 group (OE groups), VE groups + PF-04691502 and OE groups + PF-04691502. ( D ) N-cadherin and Vimentin protein levels were measured by WB using the paired RCC cells (ACHN and 786–0) in knockdown KIN17 group and different using PF-04691502 groups.

Article Snippet: The membranes were then blocked with 5% non-fat milk in TBS/Tween (0.05% Tween-20 in TBS) for 2 h. Membranes were incubated with primary antibodies including KIN17(Santa Cruz, Catalog number: sc-32768, 1:500), AKT (Proteintech, Catalog number: 60203–2-Ig, 1:10,000), mTOR (Proteintech, Catalog number: 66888–1-Ig, 1:10,000), PI3K(CST, Catalog number: 11889, 1:1000), p-AKT(CST, Catalog number: 4060S, 1:2000), p-mTOR(CST, Catalog number: 5536S, 1:1000), p-PI3K(CST, Catalog number: 17366S, 1:1000), N-cadherin (Proteintech, Catalog number: 22018–1-AP, 1:10,000), Vimentin (Proteintech, Catalog number: 10366–1-AP, 1:50,000) and GAPDH (Proteintech, 60,004–1-lg, 1:10,000) overnight at 4°C and then with secondary antibodies (anti-rabbit or anti- mouse; Proteintech) for room temperature.

Techniques: Expressing, Knockdown, In Vitro, Plasmid Preparation, Over Expression

Journal: Scientific Reports

Article Title: KIN17 facilitates the initiation and progression of renal tumor progression through the PI3K-AKT-mTOR pathway

doi: 10.1038/s41598-026-35851-5

Figure Lengend Snippet: KIN17 promotes tumor growth and suppression of tumor growth by PF-04691502 in vivo ( A ) Representative images of xenograft tumors 786–0 cells with expression of shNC and shKIN17 (n = 7 in each group). Tumor volume and tumor weight were analyzed. ( B ) Representative H&E staining and immunohistochemstry staining of Ki67, TUNEL, KIN17, p-mTOR and p-AKT in the xenograft tumor tissues (× 400 magnification). ( C ) Representative images of xenograft tumors 786–0 cells with expression of Vector, Vector + PF-04691502, OE and OE + PF-04691502 (n = 8 in each group). Tumor volume and tumor weight were analyzed. ( D ) Representative H&E staining and immunohistochemstry staining of Ki67, TUNEL, KIN17, p-mTOR and p-AKT in the xenograft tumor tissues (× 400 magnification). The error bars represent the mean ± SD of triplicate technical replicates. * P < 0.05, ** P < 0.01, ***P < 0.001.

Article Snippet: The membranes were then blocked with 5% non-fat milk in TBS/Tween (0.05% Tween-20 in TBS) for 2 h. Membranes were incubated with primary antibodies including KIN17(Santa Cruz, Catalog number: sc-32768, 1:500), AKT (Proteintech, Catalog number: 60203–2-Ig, 1:10,000), mTOR (Proteintech, Catalog number: 66888–1-Ig, 1:10,000), PI3K(CST, Catalog number: 11889, 1:1000), p-AKT(CST, Catalog number: 4060S, 1:2000), p-mTOR(CST, Catalog number: 5536S, 1:1000), p-PI3K(CST, Catalog number: 17366S, 1:1000), N-cadherin (Proteintech, Catalog number: 22018–1-AP, 1:10,000), Vimentin (Proteintech, Catalog number: 10366–1-AP, 1:50,000) and GAPDH (Proteintech, 60,004–1-lg, 1:10,000) overnight at 4°C and then with secondary antibodies (anti-rabbit or anti- mouse; Proteintech) for room temperature.

Techniques: In Vivo, Expressing, Staining, TUNEL Assay, Plasmid Preparation

Journal: Frontiers in Behavioral Neuroscience

Article Title: Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics

doi: 10.3389/fnbeh.2015.00062

Figure Lengend Snippet: mTOR signaling pathway is required for neurite elongation induced by 5-HT7R stimulation . Cortical neurons were treated for 2 h with the 5-HT7R selective agonist LP-211 (LP, 100 nM), or the mTOR inhibitors rapamycin (RAPA, 20 nM), or torin 1 (TR1, 250 nM) with or without LP. (A) Representative Tuj1 immunostaining of neuronal cultures (magnification 20x). The images in the lower row are the same of the upper row with the addition of the dashed yellow lines manually drawn by the operator from the soma (yellow circle) to the end of the primary neurite in order to measure neurite length. (B) The graph shows the neurite length expressed as percentage of values measured in the corresponding vehicle-treated cultures (CTRL, set to 100%). The bars represent means ± SEM from randomly selected fields for each cell culture condition ( n = 9). Asterisk (*): value significantly different from CTRL by One Way ANOVA followed by Dunnett post-hoc test ( p < 0.05).

Article Snippet: The mTOR inhibitors rapamycin (Sigma-Aldrich) and torin 1 (Tocris), were used at a final concentration of 20 and 250 nM, respectively.

Techniques: Immunostaining, Cell Culture

Journal: Frontiers in Behavioral Neuroscience

Article Title: Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics

doi: 10.3389/fnbeh.2015.00062

Figure Lengend Snippet: Stimulation of 5-HT7R activates mTORC1 signaling . Cortical neurons were treated for 2 h with the 5-HT7R selective agonist LP-211 (LP, 100 nM), or the mTOR inhibitor torin 1 (TR1, 250 nM), alone or in combination. (A) The bars show the level of p70S6K phosphorylation at Thr389 (means ± SEM, n = 6), expressed as percentage of values measured in the corresponding vehicle-treated cultures (CTRL, set to 100%). The level of p70S6K phosphorylation was measured by Western blot as intensity of p70S6K phosphorylated at Thr389 (p-p70S6K) normalized with that of total (phosphorylated and unphosphorylated) p70S6K in the same samples. The inset displays representative blots probed with antibodies against p-p70S6K and p70S6K; the molecular weights (kDa) are shown on the right. (B) The bars show the level of Akt phosphorylation at Ser473 (means± SEM, n = 3), expressed as percentage of values measured in the corresponding vehicle-treated cultures (CTRL, set to 100%). The level of Akt phosphorylation was measured by Western blot as intensity of Akt phosphorylated at Ser473 (p-Akt) normalized with that of total Akt (Akt) in the same samples. The inset displays representative blots probed with antibodies against p-Akt and Akt; the molecular weights (kDa) are shown on the right. Asterisk (*): value significantly different from CTRL by One Way ANOVA followed by Dunnett post-hoc test ( p < 0.05).

Article Snippet: The mTOR inhibitors rapamycin (Sigma-Aldrich) and torin 1 (Tocris), were used at a final concentration of 20 and 250 nM, respectively.

Techniques: Phospho-proteomics, Western Blot

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Article Title: Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro.

doi: 10.1111/tri.12617

Figure Lengend Snippet: Figure 1 Intracellular concentrations of TAC in human islets. Human islets were cultured with TAC (10 or 30 lg/l), SRL (10 or 30 lg/l), or the combi- nation thereof for 24–48 h before the intracellular concentration of TAC was measured in islet lysate and normalized to total protein as detailed in methods. Data are presented as the mean SD, n = 6 for each group. TAC, tacrolimus; SRL, sirolimus; *P < 0.04; ** P < 0.007; *** P < 0.0006.

Article Snippet: The islets were exposed to 10 and 30 lg/l of tacrolimus (Santa Cruz Biotechnology, Dallas, TX, USA) or sirolimus (Toronto Research Chemicals, Toronto, Ontario, Canada) or the combination thereof for 24 h and 48 h at 37 °C (5% CO2).

Techniques: Cell Culture, Concentration Assay

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Article Title: Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro.

doi: 10.1111/tri.12617

Figure Lengend Snippet: Figure 2 Intracellular concentrations of SRL in human islets. Human islets were cultured with TAC (10 or 30 lg/l), SRL (10 or 30 lg/l), or the combi- nation thereof for 24–48 h before the intracellular concentration of SRL was measured in islet lysate and normalized to total protein as detailed in methods. Data are presented as the mean SD, n = 6 for each group. TAC: tacrolimus; SRL: sirolimus; *** P < 0.001; **** P < 0.0001.

Article Snippet: The islets were exposed to 10 and 30 lg/l of tacrolimus (Santa Cruz Biotechnology, Dallas, TX, USA) or sirolimus (Toronto Research Chemicals, Toronto, Ontario, Canada) or the combination thereof for 24 h and 48 h at 37 °C (5% CO2).

Techniques: Cell Culture, Concentration Assay

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Article Title: Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro.

doi: 10.1111/tri.12617

Figure Lengend Snippet: Figure 3 Effect of CsA on intracellular concentration of SRL in human islets. Human islets were cultured with the combination of SRL (30 lg/l) and CsA (5 lg/ml), or the drug alone for 24 h before the intracellular concentration of SRL (a) or CsA (b) was measured in islet lysate and nor- malized to total protein as detailed in methods. Data are calculated as percentages of control and are presented as mean SD, n = 6 for each group. CsA, cyclosporine A; SRL, sirolimus.

Article Snippet: The islets were exposed to 10 and 30 lg/l of tacrolimus (Santa Cruz Biotechnology, Dallas, TX, USA) or sirolimus (Toronto Research Chemicals, Toronto, Ontario, Canada) or the combination thereof for 24 h and 48 h at 37 °C (5% CO2).

Techniques: Concentration Assay, Cell Culture, Control

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Article Title: Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro.

doi: 10.1111/tri.12617

Figure Lengend Snippet: Figure 4 The effect of SRL, TAC, or CsA on phosphorylation of p70S6k in islets. Human islets were cultured with TAC (30 lg/l), SRL (30 lg/l), or the combination thereof for 24 h before the presence of p- p70s6k was assessed by the cell-signaling Bio-Plex assay in human islet cell lysate and normalized to total protein (a). In a parallel experiment, human islets were cultured with SRL (30 lg/l), CsA (5 lg/ml), or the combination thereof for 24 h before p-p70S6k was detected in the lysate and normalized to total protein. Data are calculated as ratio to control and are presented as mean SD, n = 3–6 for each group. TAC, tacrolimus; SRL, sirolimus; CsA, cyclosporine A, ** P < 0.01, **** P < 0.0001.

Article Snippet: The islets were exposed to 10 and 30 lg/l of tacrolimus (Santa Cruz Biotechnology, Dallas, TX, USA) or sirolimus (Toronto Research Chemicals, Toronto, Ontario, Canada) or the combination thereof for 24 h and 48 h at 37 °C (5% CO2).

Techniques: Phospho-proteomics, Cell Culture, Plex Assay, Control

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Article Title: Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro.

doi: 10.1111/tri.12617

Figure Lengend Snippet: Figure 5 Oxygen consumption rates (OCR) in human islets after treatment of TAC, SIR, or SIR+TAC. Human islets were cultured with TAC (30 lg/l), SIR (30 lg/l), or a combination thereof for 24 h before the glucose-stimulated OCR was measured as indicated in methods. OCR is expressed as percentage of baseline and is presented as the mean SD, n = 6 for each group. TAC, tacrolimus; SRL, sirolimus, ** P < 0.01.

Article Snippet: The islets were exposed to 10 and 30 lg/l of tacrolimus (Santa Cruz Biotechnology, Dallas, TX, USA) or sirolimus (Toronto Research Chemicals, Toronto, Ontario, Canada) or the combination thereof for 24 h and 48 h at 37 °C (5% CO2).

Techniques: Cell Culture

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Article Title: Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro.

doi: 10.1111/tri.12617

Figure Lengend Snippet: Figure 6 Expression of ABCB1 (Pgp), OATP1B1, and CYP3A4 in human islets. Human islets were cultured for 24 h before the expression of the drug transporter (ABCB1(Pgp) and OATP1B1), and the metabolic enzyme CYP3A4 was evaluated. RNA was prepared and subjected to qPCR as detailed in methods. The reference gene index is calculated by the mean of ALAS1, B2M, and RPL13A expression and used to normalize the expression of target genes in isolated hepatocytes relative to the mRNA level of ABCB1(Pgp), OATP1B1, and CYP3A4 in human islets (a). OATB1 mRNA expression in human islets was normalized to reference gene index after exposure to TAC (30 lg/l), SRL (30 lg/l), or a combination thereof for 24 h (b). Represen- tative immunofluorescence image of dispersed human islets stained for insulin (green), ABCB1(Pgp) (red) and nuclear staining with DAPI (blue) (c), or glucagon (green), ABCB1(Pgp) (red) and nuclear staining wit DAPI (blue) (d). Data are presented as mean SD, n = 4–5 for each group. TAC, tacroli- mus; SRL, sirolimus; *P < 0.05; ** P < 0.01.

Article Snippet: The islets were exposed to 10 and 30 lg/l of tacrolimus (Santa Cruz Biotechnology, Dallas, TX, USA) or sirolimus (Toronto Research Chemicals, Toronto, Ontario, Canada) or the combination thereof for 24 h and 48 h at 37 °C (5% CO2).

Techniques: Expressing, Cell Culture, Isolation, Staining